Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Academic Article uri icon

Overview

abstract

  • Prodrugs of dynemicin analogs were synthesized, and their activation by aldolase antibody (Ab) 38C2 was evaluated by DNA-cleaving activity, as well as tumor cell growth inhibition. Further, we provide evidence that the activated enediynes underwent covalent crosscoupling with the aldolase Ab, which appears to be a limiting factor of their tumor cell growth-inhibiting activity and should be of general interest in the field of enediyne chemotherapy. These findings might open new avenues for defined conjugations of small molecule drugs to mAbs in general and aldolase Abs in particular.

publication date

  • February 23, 2004

Research

keywords

  • Anthraquinones
  • Antibiotics, Antineoplastic
  • Antibodies, Catalytic
  • Fructose-Bisphosphate Aldolase

Identity

PubMed Central ID

  • PMC365749

Scopus Document Identifier

  • 1542267801

Digital Object Identifier (DOI)

  • 10.1073/pnas.0307319101

PubMed ID

  • 14981258

Additional Document Info

volume

  • 101

issue

  • 9